molgramostim + antimycobacterial regimen

**molgramostim + antimycobacterial regimen** is a therapeutic combination involving **molgramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, rhGM-CSF) administered by inhalation, together with standard guideline-based antimycobacterial drugs, for the treatment of refractory pulmonary nontuberculous mycobacterial (NTM) infections including _Mycobacterium avium_ complex (MAC) and _Mycobacterium abscessus_ (MABS)[1][2]. Molgramostim acts as an **immunomodulator** by stimulating alveolar macrophage function and promoting enhanced clearance of pathogens from the lungs, while the antimycobacterial drugs act synergistically or additively to suppress mycobacterial growth[1][2][4]. The regimen is under investigation in patients with cystic fibrosis and other populations suffering from chronic NTM lung disease, and is considered for patients with refractory infection who may not respond to antimycobacterial therapy alone[1][2][5].

Brand names

Molgradex

Other names

molgramostim + antimycobacterial regimengranulocyte macrophage-colony stimulating factor + antimycobacterial drugs